Partner Therapeutics to focus on commercial and late-stage cancer therapies.
BOSTON, Jan. 25, 2018-PRNewswire
Biotech and pharmaceutical executives Robert Mulroy and Dr. Debasish Roychowdhury announced today the launch of Partner Therapeutics, or PTx, an oncology company that is focused on the development and commercialization of approved and late-stage therapies. The Boston-area company is committed to supporting patient care with medicines that improve cancer treatment outcomes and reduce the total cost of care.
Mr. Mulroy and Dr. Roychowdhury are biopharma veterans who combined have overseen the approval and launch of over a dozen new oncology products; the discovery and development of over 50 novel cancer programs; the growth and development of multiple new startups from conception through IPO or sale; and the execution of business development and financial transactions totaling over $3B to support the discovery, development, and commercialization of cancer therapies.
Dr. Roychowdhury will serve as Chief Medical Officer and Director of the company. He is a medical oncologist and a proven c-suite executive in the pharmaceutical industry with over 15 years of senior management experience and 14 years of patient care, academic research and teaching experience. Prior to PTx, he served as senior vice president and global head of oncology at Sanofi, vice president for clinical development at GlaxoSmithKline, head of the global oncology regulatory group at Eli Lilly and Company, and most recently, the chief medical officer of Seragon, through the company’s acquisition by Roche.
Mr. Mulroy will serve as Chairman and Chief Executive Officer of PTx. He has 25 years of experience in the biopharmaceutical and healthcare sector, having led the development of multiple biotech companies and served as an industry consultant. Prior to PTx he served as co-founder, CEO and director of Merrimack Pharmaceuticals and as director and CEO of Atlantic Bio. He has extensive experience in a comprehensive range of capital raises, strategic transactions, and organizational development spanning research, development and commercial capabilities.
“Debasish and I share a passion for improving patient outcomes in the treatment of cancer,” said Mr. Mulroy. “We formed PTx to address gaps in treatment and improve cost effectiveness of cancer care through a mission-driven organization focused on exceptional execution on behalf of patients.”
“We are committed to building a company that serves as a true partner to improve patient care,” said Dr. Roychowdhury. “We believe PTx can serve as a critical link between the investigators pushing the boundaries of our understanding of cancer and the healthcare professionals working to achieve the best outcomes for each and every patient.”
PTx will build its product portfolio through the acquisition of programs with the promise to deliver on improved health and economic outcomes. The company plans to operate as an integrated commercial, development and manufacturing organization.
About Partner Therapeutics (PTx):
PTx is an integrated biotech company focused on the development and commercialization of late-stage therapeutics that improve the health and economic outcomes in the treatment of cancer. PTx’s development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering products and supporting medical teams with the purpose of achieving superior outcomes for patients and their families.